Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified May 2009 by Mahidol University.
Recruitment status was:  Active, not recruiting
Information provided by:
Mahidol University Identifier:
First received: May 3, 2009
Last updated: NA
Last verified: May 2009
History: No changes posted

Post-operative nausea and vomiting are the major complications after spinal anesthesia with intrathecal morphine, therefore antiemetic drugs should be administered for best satisfaction of anesthesia to prevent these complication.

Furthermore, administration of a combination of antiemetic drugs with different mechanisms of action appears reasonable and synergistic effect of drugs.

In conclusion, we study efficacy of antiemetic effect of single antiemetic drug compare with combination antiemetic drugs.

Condition Intervention
Drug: dexamethasone
Drug: dexamethasone 5 mg

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Efficacy of Prevention for Postoperative Nausea and Vomiting After Intrathecal Morphine in Cesarean Section: a Randomized Comparison of Metoclopramide or Ondansetron Alone or in the Combination With Dexamethasone.

Resource links provided by NLM:

Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • nausea and vomiting after spinal anesthesia with intrathecal morphine in cesarean section [ Time Frame: 24 hrs post operatively ]

Secondary Outcome Measures:
  • Secondary outcome measurement 1. Sedation score 2. Pain score 3. Itching symptom 4. Patient satisfaction [ Time Frame: 24 Hrs post operatively ]

Enrollment: 120
Study Start Date: May 2009
Estimated Study Completion Date: April 2011
Estimated Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: 1
Metoclopramide 10 mg intravenous
No Intervention: 2
Ondansetron 8 mg intravenous
Active Comparator: 3
dexamethasone 5 mg and metoclopramide 10 mg
Drug: dexamethasone
Metoclopramide 10 mg and dexamethasone 5 mg intravenous
Other Name: Dexamo
Active Comparator: 4
dexamethasone 5 mg and ondansetron 8 mg IV
Drug: dexamethasone 5 mg
Ondansetron 8 mg and dexamethasone 5 mg IV
Other Name: Dexamo

Detailed Description:

In this study : a randomized, double-blind, placebo-controlled, clinical trial comparing single doses of Metoclopramide 10 mg and Ondansetron 8 mg alone and a combination of Dexamethasone 5 mg and Metoclopramide 10 mg or a combination of Dexamethasone 5 mg and Ondansetron 8 mg for prevention of PONV after spinal morphine for cesarean section.

Inclusion criteria

  1. Patient undergoes elective cesarean section age more than 18 years
  2. Patient accepted in spinal anesthesia technique
  3. ASA classification I-II
  4. Patient understand question and evaluation process

Exclusion criteria

  1. Hyperemesis gravidarum
  2. Patient with ongoing antiemetic drugs treatment
  3. Patient with history of drug allergy in Metoclopramide,Ondansetron and Dexamethasone

Outcome measurement By oral interview and nurse notification in 24 hr. post-operatively.

Detail of outcome measurement

  1. Nausea and vomiting score
  2. Pain score
  3. Sedation score
  4. Itch symptom
  5. Patient satisfaction

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Pregnancy patients undergo Elective cesarean section age more than 18 years
  • Patient accept spinal anesthesia technique
  • ASA classification I-II
  • Patient understand question and evaluation process

Exclusion criteria:

  • Hyperemesis gravidarum
  • Patient ongoing treatment with antiemetic drugs
  • Allergy to Metoclopramide,Ondansetron and Dexamethasone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00892996

Anesthesiology department, Siriraj hospital, Mahidol University
Bangkok, Thailand, 10700
Sponsors and Collaborators
Mahidol University
Principal Investigator: Patchareya Nivatpumin, M.D. Anesthesiology department, Siriraj hospital, Mahidol University
  More Information

Responsible Party: Siriraj institutional review board, mahidol university Identifier: NCT00892996     History of Changes
Other Study ID Numbers: Si 9091/2552(EC2)
Study First Received: May 3, 2009
Last Updated: May 3, 2009

Keywords provided by Mahidol University:
Intrathecal morphine
Cesarean section
Nausea and vomiting

Additional relevant MeSH terms:
Postoperative Nausea and Vomiting
Signs and Symptoms, Digestive
Signs and Symptoms
Postoperative Complications
Pathologic Processes
Dexamethasone acetate
Dexamethasone 21-phosphate
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Analgesics, Opioid
Narcotics processed this record on April 28, 2017